SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guidant (GDT) -- Ignore unavailable to you. Want to Upgrade?

To: LJM who wrote (99)4/1/1998 12:43:00 PM
From: Tom  Respond to of 235
 
CRM (defibrillators and pacemakers) make up 40% of current GDT revenues. VI is now 55% and other CVS, etc. is <5%. this is the new figures from 4th qtr. and the significant growth in VI due to the stent momentum. Also, GP from a VI dollar is 2x that of CRM. Hence, gross margins and EPS benefit tremendously.



To: LJM who wrote (99)4/3/1998 4:46:00 AM
From: Cook  Read Replies (2) | Respond to of 235
 
Yeah. Expect about $400 million in stent sales in 1998, based on $100M US in the last quarter of 97, reduced by expected share gains by AVEI and BSX, adding in Europe and Japan


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News